We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 81-96 of 96 results
  1. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH

    The ability of the multidrug resistance modifiers R- and R,S-verapamil (VPL), cyclosporine A (CsA) and its non-immunosuppressive derivative SDZ PSC...

    Johannes Zacherl, Gerhard Hamilton, ... Etienne Wenzl in Cancer Chemotherapy and Pharmacology
    Article 01 March 1994
  2. Polarisierte Monolayerkulturen zur In-vitro-Untersuchung des intestinalen P-Glykoproteinmediierten Transports

    Background: Mechanisms of drug resistance both at the tumor and cellular level are mainly responsible for the observed low response rates and...

    J. Zacherl, G. Hamilton, ... E. Wenzl in Acta Chirurgica Austriaca
    Article 01 November 1994
  3. Multidrug resistance in human cancer

    Resistance to cytotoxic chemotherapy continues to be a major obstacle to more effective treatment of human cancers. A particular problem in clinical...

    Article 01 October 1994
  4. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells

    The multidrug transporter, P-glycoprotein (P-gp), is expressed by CD34-positive bone marrow cells, which include hematopoietic stem cells, and in...

    T. Licht, I. Pastan, ... F. Herrmann in Annals of Hematology
    Article 01 October 1994
  5. The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat

    the feasibility of using chemosensitizers in the circumvention of P-glycoprotein-mediated multidrug resistance has been shown in many studies. We...

    W. Van de Vrie, A. M. Jonker, ... A. M. M. Eggermont in Journal of Cancer Research and Clinical Oncology
    Article 01 September 1994
  6. Clinical Pharmacokinetics of Paclitaxel

    Paclitaxel is a new anticancer agent showing significant promise as therapy for solid tumours and leukaemia, given alone or in combination with other...

    Daryl S. Sonnichsen, Mary V. Relling in Clinical Pharmacokinetics
    Article 01 October 1994
  7. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance

    A series of five potential modulators of resistance were tested for their relative ability, as compared with verapamil, to sensitize CEM...

    Bridget T. Hill, Louise K. Hosking in Cancer Chemotherapy and Pharmacology
    Article 01 July 1994
  8. Pharmacokinetic Drug Interactions with Anticancer Drugs

    Drug dosage is of paramount importance in the treatment of cancer, the aim being to optimise drug exposure with a view to maximising antitumour...

    Paul M. Loadman, Mike C. Bibby in Clinical Pharmacokinetics
    Article 01 June 1994
  9. Multidrug resistance in cancer chemotherapy

    Resistance to chemotherapy is the single most important reason for treatment failure in cancer patients. Over the past 15 years, we have gained...

    Nomita H. Patel, Mace L. Rothenberg in Investigational New Drugs
    Article 01 March 1994
  10. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour

    Colon tumours are intrinsically resistant to chemotherapy and most of them express the multidrug transporter P glycoprotein (Pgp). Whether this Pgp...

    W. Van de Vrie, E. E. O. Gheuens, ... A. M. M. Eggermont in Journal of Cancer Research and Clinical Oncology
    Article 01 October 1993
  11. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20′-vinblastine congeners that lack antimicrotubule activity

    Seven binary vinca alkaloid congeners were newly synthesized as the C14′ or C16′(20′) or C14′16′(20′) stereoisomers of C20′-modified VBL. These...

    Linda S. Borman, William G. Bornmann, Martin E. Kuehne in Cancer Chemotherapy and Pharmacology
    Article 01 September 1993
  12. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype

    The new non-immunosuppressive cyclosporin derivative SDZ PSC 833 (PSC) is a potent agent used to overcome typical multidrug resistance (MDR)...

    Peter A. W. te Boekhorst, Jan van Kapel, ... Pieter Sonneveld in Cancer Chemotherapy and Pharmacology
    Article 01 May 1992
  13. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor

    Recent studies by Boesch et al. have demonstrated that a nonimmunosuppressive cyclosporin analog, SDZ PSC 833 (an analog of cyclosporin D), is an...

    Ellen Friche, Peter Buhl Jensen, Nis I. Nissen in Cancer Chemotherapy and Pharmacology
    Article 01 May 1992
  14. In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia

    A 72 hours fluorometric microculture cytotoxicity assay (FMCA) was used for the study of chemotherapeutic drug resistance in tumor cell suspensions...

    Jörgen Kristensen, Bertil Jonsson, ... Rolf Larsson in Medical Oncology and Tumor Pharmacotherapy
    Article 01 June 1992
Did you find what you were looking for? Share feedback.